Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylactic mastectomy.

L A Newman1, H M Kuerer, K K Hung

  • 1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Journal of the American College of Surgeons
|September 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case report of a fibrin-associated large B-cell lymphoma presenting as a retroperitoneal cystic tumour mimicking an atypical pheochromocytoma.

Journal of surgical case reports·2026
Same author

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.

Nature medicine·2021
Same author

Extracellular levels of glucose in the hippocampus and striatum during maze training for food or water reward in male rats.

Behavioural brain research·2021
Same author

Correction to: Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT.

EJNMMI research·2020
Same author

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT.

EJNMMI research·2020
Same author

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Prophylactic mastectomy may reduce breast cancer risk by up to 90% in high-risk individuals. However, its benefits, including impact on longevity and quality of life, require careful consideration against alternatives.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Preventive Medicine

Background:

  • The Society of Surgical Oncology provides guidelines for prophylactic mastectomy.
  • Limited data exist on the efficacy of prophylactic mastectomy in humans.
  • Prophylactic mastectomy is a risk-reduction strategy for breast cancer.

Purpose of the Study:

  • To review the indications and outcomes of prophylactic mastectomy.
  • To discuss the benefits and limitations of prophylactic mastectomy.
  • To inform patients about risk-reduction alternatives.

Main Methods:

  • Review of existing literature and position statements.
  • Analysis of data on risk reduction and survival.
  • Consideration of quality of life and cosmetic outcomes.

Related Experiment Videos

Main Results:

  • Prophylactic mastectomy may reduce breast cancer risk by up to 90%.
  • Benefits for BRCA mutation carriers may improve longevity but impact quality of life.
  • Contralateral prophylactic mastectomy in unilateral cancer is unlikely to improve survival.

Conclusions:

  • Prophylactic mastectomy is not an absolute indication procedure.
  • Benefits must be weighed against quality of life and alternatives like chemoprevention.
  • Informed patient consent regarding risks, benefits, and limitations is crucial.